news
Lilly and Novo Share Early GLP-1 Longevity Research
Novo Nordisk and Eli Lilly presented early research on GLP-1s at Harvard's ARDD conference, linking the drugs to improved healthspan and anti-aging benefits. This moves beyond weight loss to explore their potential in delaying age-related decline. It's a peek at how pharma is thinking about GLP-1s long-term.
Novo Nordisk and Eli Lilly presented early research on GLP-1s at Harvard's ARDD conference, linking the drugs to improved healthspan and anti-aging benefits. This moves beyond weight loss to explore their potential in delaying age-related decline. It's a peek at how pharma is thinking about GLP-1s long-term.
The architecture take
The pharma giants aren't just talking about weight loss anymore; they're pitching GLP-1s as longevity tools. Novo and Lilly's data presented at Harvard's ARDD conference shows them actively measuring GLP-1's impact on 'healthspan' and 'aging.' This isn't about looking younger, it's about shifting the conversation to systemic effects on the body – inflammation, cellular health, metabolic regulation, the whole package. If these drugs can truly delay age-related decline, that's a massive market. For now, it means more research dollars pouring into understanding exactly how GLP-1s work beyond just blood sugar and appetite control. I'm watching to see if this leads to new formulations or indications, specifically for longevity. Because once you've addressed weight, where do you go next with a drug that has this much metabolic power?